Timothy E. Van Meter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Timothy E. Van Meter has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Helen L. Fillmore
University of Portsmouth, Portsmouth, UK
2 shared publications William C. Broaddus
2 shared publicationsCarleton Garrett
1 shared publicationCatherine Dumur
1 shared publicationDana Cash
1 shared publicationNaiel Hafez
1 shared publication
Latest Publications
- 1 December 2006
- Published by Wolters Kluwer Health in Diagnostic Molecular Pathology
- Vol. 15 (4) , 195-205
Microarray Analysis of MRI-defined Tissue Samples in Glioblastoma Reveals Differences in Regional Expression of Therapeutic Targets
Microarray technologies have come into prominence for the assessment of molecular diagnostic profiles in cancer tissue biopsies. To better understand the effect of sampling bias, we paired image-guided stereotactic biopsy and microarray technology to study regional intratumoral differences in tumor periphery and core regions of untreated glioblastoma. RNA was extracted from serial frozen sections using an integral histopathologic scoring approach. Gene expression analysis was performed using high-density oligonucleotide microarrays (22,283 probe sets). A consensus list of 643 genes (784 probe sets) with greater than 2-fold difference between intratumoral periphery and core samples was obtained using Microarray Suite 5.0, model-based expression indexes, and robust multiarray analysis algorithms. Results were validated using quantitative polymerase chain reaction and Western blotting analyses. Reproducible profiles emerged, in which multiple therapeutic targets significant to glioblastoma [matrix metalloproteinases, AKT1 (v-akt murine thymoma viral oncogene homolog 1), epidermal growth factor receptor, vascular endothelial growth factor] showed significant differences in regional expression that may affect treatment response. This study suggests important intratumoral regional differences in the molecular phenotype of glioblastoma.
- 1 December 2006
- Published by Wolters Kluwer Health in Diagnostic Molecular Pathology
- Vol. 15 (4) , 195-205
Microarray Analysis of MRI-defined Tissue Samples in Glioblastoma Reveals Differences in Regional Expression of Therapeutic Targets
Microarray technologies have come into prominence for the assessment of molecular diagnostic profiles in cancer tissue biopsies. To better understand the effect of sampling bias, we paired image-guided stereotactic biopsy and microarray technology to study regional intratumoral differences in tumor periphery and core regions of untreated glioblastoma. RNA was extracted from serial frozen sections using an integral histopathologic scoring approach. Gene expression analysis was performed using high-density oligonucleotide microarrays (22,283 probe sets). A consensus list of 643 genes (784 probe sets) with greater than 2-fold difference between intratumoral periphery and core samples was obtained using Microarray Suite 5.0, model-based expression indexes, and robust multiarray analysis algorithms. Results were validated using quantitative polymerase chain reaction and Western blotting analyses. Reproducible profiles emerged, in which multiple therapeutic targets significant to glioblastoma [matrix metalloproteinases, AKT1 (v-akt murine thymoma viral oncogene homolog 1), epidermal growth factor receptor, vascular endothelial growth factor] showed significant differences in regional expression that may affect treatment response. This study suggests important intratumoral regional differences in the molecular phenotype of glioblastoma.
- Open Access
Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas
BACKGROUND.: Heightened activity of the AKT signaling pathway is prominent in malignant gliomas and has been suggested to play a role in treatment resistance. Selective targeting of AKT, therefore, may increase chemosensitivity. Recently, a novel class of AKT‐selective inhibitors has been described, including SH‐6, a phosphatidylinositol analogue.METHODS.: The effects of SH‐6 on AKT signaling were tested in glioma cells, and the putative role of AKT signaling in chemoresistance was tested by attenuating AKT signaling pharmacologically and genetically. The initial characterization of SH‐6 included treatment of glioma cells with increasing doses of SH‐6 (0.30–30 μM) and examining the effects on AKT signaling proteins by Western blot analyses and in kinase assays with immunoprecipitated AKT1. Dose‐response studies with SH‐6 administered to glioma cell lines were performed using a luminescent cell‐viability assay (0.1–30 μM). Studies examining the effect of carmustine, either alone or in combination with either the phosphatidylinositol 3‐kinase inhibitor LY294002 or SH‐6, were performed by cell viability assays and clonogenic survival assays. The effect of carmustine on AKT activity as a response to treatment also was examined. Caspase assays were used to examine the potential role of apoptosis in SH‐6/ carmustine ‐elicited cell death. Finally, the induction of a dominant‐negative AKT1 transgene was used in combination with carmustine to demonstrate the role of AKT1 in carmustine chemoresistance.RESULTS.: Serum‐stimulated phosphorylation of AKT1 was inhibited by SH‐6 at doses ≥10 μM (>70% decrease in Threonine 308 and Serine 473 phosphorylation of AKT1). In adenosine triphosphate assays, 72 hours of treatment with SH‐6 led to 50% lethal doses near 10 μM for 2 cell lines tested. SH‐6 enhancement of carmustine‐mediated cell death led to synergistic increases in Caspase 3/Capsase 7 activity, implicating apoptosis as the cell death mechanism. In clonogenic assays, SH‐6 cotreatment with carmustine significantly decreased the number of colonies at 10 μM (P < .05) compared with carmustine alone. No decrease was observed in cells that were treated with SH‐6 alone (10 μM). LY294002 (10 μM) was also able to enhance the effects of carmustine significantly in both cell lines.CONCLUSIONS.: In the current study, the authors characterized the efficacy of a new class of adjuvant chemotherapeutics that show promise in enhancing the efficacy of standard chemotherapy regimens in gliomas. Cancer 2006. © 2006 American Cancer Society.
Open AccessCotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas
BACKGROUND.: Heightened activity of the AKT signaling pathway is prominent in malignant gliomas and has been suggested to play a role in treatment resistance. Selective targeting of AKT, therefore, may increase chemosensitivity. Recently, a novel class of AKT‐selective inhibitors has been described, including SH‐6, a phosphatidylinositol analogue.METHODS.: The effects of SH‐6 on AKT signaling were tested in glioma cells, and the putative role of AKT signaling in chemoresistance was tested by attenuating AKT signaling pharmacologically and genetically. The initial characterization of SH‐6 included treatment of glioma cells with increasing doses of SH‐6 (0.30–30 μM) and examining the effects on AKT signaling proteins by Western blot analyses and in kinase assays with immunoprecipitated AKT1. Dose‐response studies with SH‐6 administered to glioma cell lines were performed using a luminescent cell‐viability assay (0.1–30 μM). Studies examining the effect of carmustine, either alone or in combination with either the phosphatidylinositol 3‐kinase inhibitor LY294002 or SH‐6, were performed by cell viability assays and clonogenic survival assays. The effect of carmustine on AKT activity as a response to treatment also was examined. Caspase assays were used to examine the potential role of apoptosis in SH‐6/ carmustine ‐elicited cell death. Finally, the induction of a dominant‐negative AKT1 transgene was used in combination with carmustine to demonstrate the role of AKT1 in carmustine chemoresistance.RESULTS.: Serum‐stimulated phosphorylation of AKT1 was inhibited by SH‐6 at doses ≥10 μM (>70% decrease in Threonine 308 and Serine 473 phosphorylation of AKT1). In adenosine triphosphate assays, 72 hours of treatment with SH‐6 led to 50% lethal doses near 10 μM for 2 cell lines tested. SH‐6 enhancement of carmustine‐mediated cell death led to synergistic increases in Caspase 3/Capsase 7 activity, implicating apoptosis as the cell death mechanism. In clonogenic assays, SH‐6 cotreatment with carmustine significantly decreased the number of colonies at 10 μM (P < .05) compared with carmustine alone. No decrease was observed in cells that were treated with SH‐6 alone (10 μM). LY294002 (10 μM) was also able to enhance the effects of carmustine significantly in both cell lines.CONCLUSIONS.: In the current study, the authors characterized the efficacy of a new class of adjuvant chemotherapeutics that show promise in enhancing the efficacy of standard chemotherapy regimens in gliomas. Cancer 2006. © 2006 American Cancer Society.